osimertinib + rifampicin

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations. Rifampicin is a strong CYP3A4 inducer antibiotic used for tuberculosis and other infections. The combination "osimertinib + rifampicin" refers to the co-administration of these two drugs, which results in significant pharmacokinetic interactions—rifampicin markedly reduces osimertinib plasma concentrations by increasing its metabolism via CYP3A4 induction[1][3][6]. This interaction may reduce the efficacy of osimertinib unless dose adjustments are made[1][6].

Brand names

Tagrisso (for Osimertinib)no unique brand name for combination

Other names

osimertinib and rifampicinosimertinib with rifampicin